Clinical Trial: Siponimod (BAF312, Novartis Pharmaceuticals, AG) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Siponimod (BAF312, Novartis Pharmaceuticals, AG)

Share

Details
Type of MS: SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 1530
Medication: Siponimod
Location: AL|AZ|CA|CO|CT|DE|DC|FL|IL|KS|KY|MD|MA|MI|MN|NV|NH|NJ|NM|NY|NC|OH|OK|OR|PA|RI|TN|TX|VT|VA|WA|WI
Contact Information
1-888-669-6682

Funding:

Novartis Pharmaceuticals AG

Description

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the effectiveness and safety of siponimod (BAF312) in people with secondary progressive multiple sclerosis.

Share